OSTX

OS Therapies is a clinical-stage, pre-revenue biopharma whose entire value rests on one asset, OST-HER2, in recurrent pulmonary metastatic osteosarcoma. The clinical story is genuinely strong: the Phase IIb trial hit its primary endpoint with statistical significance, and final two-year overall survival data showed 75% (27 of 36 evaluable patients) survival versus 40% in historical controls (p<0.0001), with a clean tolerability profile. Management is moving toward a BLA, with non-clinical/CMC modules submitted to the FDA in January 2026 and a clinical module to follow a Q2 2026 Type B meeting, plus conditional EMA/MHRA submissions and a potential Rare Pediatric Disease Priority Review Voucher if accelerated approval lands before September 2029. On the science alone, this is a credible shot on goal in a high unmet-need indication.

The balance sheet, however, is the dominant fact and it is dire. FY2025 closed with just $270K of cash — down 95.1% year over year — against an operating cash burn of $14.2M and a net loss that ballooned to $28.8M (R&D up 476% to $16.4M as the BLA push accelerated). Stockholders' equity is negative $6.10M, total liabilities ($11.9M) more than tripled the company's $6.84M of total assets, and current liabilities of $11.8M tower over $333K of current assets. By any reading, the company cannot fund even one more quarter of operations from its own resources; it is entirely dependent on raising external capital imminently. Shares already grew 82.5% in a single year to 39.5M, and with ~6.8M options/warrants outstanding at a $1.83 strike, existing holders face heavy, near-certain dilution at whatever price the market will bear — exactly the kind of distressed financing that caps upside even when news is good.